Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06481475

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

Led by Chongqing Claruvis Pharmaceutical Co., Ltd. · Updated on 2025-03-21

174

Participants Needed

3

Research Sites

37 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines. The objective of this study is to test the safety, efficacy, immunogenicity of YY003, and compare to vehicel control, in improving the appearance of moderate to severe glabellar lines.

CONDITIONS

Official Title

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be 18 years or older at the time of consent
  • Have moderate to severe glabellar lines at maximum frown (grade 2 or 3 on a 4-point scale) as assessed by both investigator and participant
  • Agree to use effective contraception during the study and for at least 3 months after treatment
  • Provide signed informed consent and agree to study requirements
  • Be able to complete the study and follow instructions, as judged by the investigator
Not Eligible

You will not qualify if you...

  • Allergy or hypersensitivity to any component of the study drug or any botulinum toxin serotype
  • History or presence of ptosis, significant facial asymmetry, or excessive dermatochalasis
  • History or presence of facial nerve palsy
  • Positive test for HIV, hepatitis B, or hepatitis C
  • Other diseases judged unsuitable for participation by the investigator
  • History of drug or alcohol abuse
  • History or presence of epilepsy
  • Serious mental disorder affecting compliance
  • Pregnant or breastfeeding female
  • Abnormal lab tests deemed inappropriate for participation
  • Participation in another investigational drug or device study within 30 days or 5 half-lives prior to screening
  • Study center personnel, close relatives of personnel, or employees or relatives of sponsor company employees

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

St George Dermatology & Skin Cancer Centre

Sydney, New South Wales, Australia, 2217

Actively Recruiting

2

Skin Health Institute

Melbourne, Victoria, Australia, 3053

Actively Recruiting

3

Dermatology Institute of Victoria

Melbourne, Victoria, Australia, 3141

Actively Recruiting

Loading map...

Research Team

P

Pan Lin

CONTACT

S

Sun Xiaoyun

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here